SS-31 (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Cadence is daily through the 5 to 7 day loading phase, then 2 to 3 times weekly in maintenance, given subcutaneously in the morning or 60 to 90 minutes before training. SS-31 behaves as a structural repair signal rather than continuous therapy: once cardiolipin binding sites saturate, additional dosing buys diminishing return. The 40 mg per day used in clinical trials was calibrated for Barth syndrome and primary mitochondrial myopathy, where genetic structural deficits require rescue; with intact baseline cardiolipin infrastructure, saturation is reached at 5 to 10 mg. A day 3 to 4 pattern is common during loading: the first 3 days often feel flat or mildly fatigued as mitochondria stabilize structure instead of producing output, with the shift to steadier energy, cleaner recovery, and less oxidative flare typically arriving on day 4 or 5. The full loading phase is held before the protocol is judged, since the early fatigue window is frequently mistaken for a lack of response. Sites are rotated systematically across abdomen, thighs, and upper arms; a 10 mg dose fills a full U-100 syringe at 100 units, so it stays a single injection at this concentration.

Results Timeline

Sequence described in the research record. Individual response varies.

• Days 1 to 3 of loading: output often feels flat or mildly fatigued as the repair process takes priority over energy production.
• Day 4 or 5 of loading: the shift usually arrives, with steadier energy, cleaner recovery, and less oxidative flare.
• Days 5 to 7: loading closes once cardiolipin binding sites are saturated.
• Weeks 1 to 8 of maintenance: 2 to 3 doses weekly hold membrane stability while training and recovery consolidate.
• Every 6 to 12 months: a 4 to 6 week tune-up cycle is run rather than continuous dosing.

Reconstitution Steps

1. Use ISOTONIC bacteriostatic water (0.9% sodium chloride) where available; it reduces injection site sting significantly compared with plain bacteriostatic water.
2. Draw 1.0 mL isotonic bacteriostatic water with a sterile syringe.
3. Inject slowly down the vial wall; avoid foaming.
4. Gently swirl until dissolved (do not shake).
5. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light, and use within 4 to 6 weeks. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe, so 5 mg = 50 units (0.50 mL) and 10 mg = 100 units (1.00 mL, a full syringe).

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C (minus 4 °F) in dry, dark conditions; stable for 12 plus months.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F), use within 4 to 6 weeks, and avoid freeze thaw cycles.

• Allow vials to reach room temperature before opening, which reduces condensation uptake.
• Protect from light and temperature fluctuations for the whole cycle; isotonic reconstituted solution is handled the same way as standard reconstituted peptide.

Supplies Needed

Supply math is based on a 7 day loading phase at 5 mg daily followed by 6 weeks of maintenance at 5 mg twice weekly, which is 35 mg across the loading week and 10 mg per maintenance week.

Peptide Vials (SS-31, 10 mg vial):

• The full 8 week cycle totals 95 mg (35 mg loading plus 60 mg maintenance), which is about 10 vials of 10 mg; an annual budget of 2 cycles is about 20 vials.

Insulin Syringes (U-100):

• Per week: 7 syringes during loading and 2 syringes during maintenance, one per injection.
• Full 8 week cycle: about 19 syringes (U-100, 50 or 100 unit). Annual at 2 cycles: about 40.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL of isotonic bacteriostatic water, and the plan allows one 10 mL bottle per about 5 vials, which works out to 4 to 5 bottles annually.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin.
• Full 8 week cycle: about 38 swabs across roughly 19 injections. Annual: about 80, which one 100 count box covers.

Important Notes

Practical considerations for consistency and safety.

• Isotonic bacteriostatic water (0.9% sodium chloride) is specified for SS-31 specifically: it reduces injection site sting and prevents welts. Plain bacteriostatic water works but stings more, and is fine for most other peptides.
• 5 to 10 mg is the saturation range where baseline cardiolipin is intact. The 40 mg per day clinical trial dose was calibrated to rescue near total structural deficit in Barth syndrome and primary mitochondrial myopathy, so scaling above 10 mg in healthy aging mitochondria offers diminishing return at meaningful cost.
• Day 3 to 4 fatigue during loading is expected and reflects the repair process, with the shift to steadier energy typically arriving on day 4 or 5. Discontinuing inside that early window is the most common way an adaptation period gets mistaken for a failure to respond.
• The protocol is cycled, not continuous: loading, then maintenance, then a break, with tune-up cycles every 6 to 12 months for long term resilience. Continuous high frequency dosing past binding site saturation buys nothing.
• Distinct from MOTS-c and complementary to it. MOTS-c is the software layer (signaling, biogenesis, fuel selection) and SS-31 is the hardware layer (structural repair of existing mitochondria), with NAD+ as the cofactor both require. Related use cases in the research literature include support during GLP-1 fat loss protocols, where high oxidative flux strains mitochondrial membranes, and injury recovery layered after foundational repair with BPC-157, TB-500, NAD+, GHK-Cu, and KPV when relapse under load is the bottleneck.
• Regulatory Note: SS-31 (elamipretide) received FDA approval in 2025 as Forzinity for Barth syndrome, the first therapeutic targeted to mitochondria approved in the US, granted through the accelerated pathway with a confirmatory study required after approval. For all other indications SS-31 remains investigational, and material sold for research is not for human consumption. The master sheet records no WADA classification for this compound.

How This Works

SS-31 (D-Arg-Dmt-Lys-Phe-NH2) is engineered to selectively accumulate inside mitochondria, reaching 1,000 to 5,000 times the concentration of surrounding tissue. Its target is cardiolipin, a lipid unique to the inner mitochondrial membrane that anchors the electron transport chain protein complexes (I, III, IV) and cytochrome c in position. When cardiolipin is damaged by aging, inflammation, illness, oxidative stress, alcohol, sleep disruption, or psychological stress, the membrane loosens and the energy producing machinery drifts apart, so electrons leak from the chain instead of completing the ATP synthesis cascade and reactive oxygen species are produced instead of energy. SS-31 binds cardiolipin and restores structural tension: electron transport complexes stay aligned, electron flow becomes cleaner, the membrane sustains the electrochemical gradient needed for continuous ATP production, and the mitochondrion carries less internal strain. Downstream, the tighter chain reduces electron leak and ROS spikes, SIRT1 activation enhances long term mitochondrial growth signaling, the NF-kB inflammatory switch is suppressed, glutathione antioxidant capacity is preserved, and cytochrome c stays anchored, which matters because its detachment can trigger apoptosis. Cellular ATP burn rate stabilizes, NAD+ stops being spent on PARP mediated DNA repair from oxidative damage, and CD38, the NAD+ degrading enzyme, stays low because inflammatory signaling quiets. The net effect is the reverse of typical age related decline: cleaner output, less waste, less downstream damage. These are structural corrections rather than forced output, which is also why mild fatigue can appear on day 3 to 4 of loading, while the system repairs structure before resuming full output.

Benefits & Side Effects

Observations from the published record.

• FDA approval in 2025 for Barth syndrome rested on the TAZPOWER trial, which showed multi year improvements in six minute walk distance and cardiac biomarkers, with a 168 week open label extension confirming sustained benefit and tolerability.
• The ATPmax study in older adults found that a single IV dose increased skeletal muscle ATP production, demonstrating target engagement in the population most affected by mitochondrial decline, and elamipretide exposure improved mitochondrial respiration in failing human myocardium tested outside the body.
• Trial results vary by indication: MMPOWER-3 in primary mitochondrial myopathy missed its primary endpoint while secondary outcomes showed directional benefit, and ReCLAIM-2 in dry AMD was mixed overall with a functional signal in predefined subgroups. Across studies the mechanistic signal is consistent: the compound reaches its target, stabilizes the membrane, reduces ROS, and improves efficiency.
• Reported energy patterns center on stability under load rather than stimulation: physical effort producing proportional fatigue instead of delayed crashes, shorter recovery windows, narrower day to day variability, and fewer reactive flares after heavy training days.
• NAD+ conservation is a secondary effect. Less electron leak means less PARP demand from oxidative DNA repair and less inflammation means less CD38 driven degradation, so NAD+ levels stay higher once the membrane is stabilized.
• Side effects reported are transient warmth or flushing on early doses lasting minutes, brief nausea on early doses that resolves quickly, and mild fatigue during loading that follows the repair mode pattern. No serious adverse events were dominant in published trials, including multi year Barth syndrome extension data. Precautionary contraindications are active malignancy, pregnancy or breastfeeding, and known peptide hypersensitivity; no drug interactions are characterized.

Lifestyle Factors

Complementary strategies for best outcomes.

• Sleep of 7 to 9 hours, since deep sleep is when membrane repair runs and fragmented sleep leaves restoration incomplete, working directly against the mechanism.
• Limited alcohol during cycles, because ethanol generates byproducts that challenge membrane stability, and reduced chronic stress, because stress hormones raise mitochondrial demand while suppressing repair windows.
• Hydration and electrolyte balance, since mitochondrial function depends on intact ion gradients and dehydration directly affects membrane potential.
• Pairing that covers the other levers: NAD+ as the cofactor, MOTS-c for biogenesis signaling to complete the Mito Stack, L-Carnitine when fatty acid oxidation is the downstream limiter, magnesium and CoQ10 for electron transport and ATP utilization, plus resistance training and zone 2 cardio so adaptation has structural stability to consolidate against.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Szeto HH, Liu S. Cardiolipin targeted SS-31 mechanism: mitochondrial concentration and respiratory complex stabilization (Int J Mol Sci, 2025).
2. Thompson WR, Hornby B et al. TAZPOWER Phase 2/3 in Barth syndrome, basis for FDA approval (Genet Med, 2021).
3. Thompson WR, Manuel R et al. TAZPOWER 168 week extension in Barth syndrome (Genet Med, 2024).
4. Siegel MP, Kruse SE et al. ATPmax: single IV dose increases skeletal muscle ATP in older adults (PLoS ONE, 2021).
5. Sabbah HN, Gupta RC et al. Elamipretide improves mitochondrial respiration in failing human myocardium (JACC Basic Transl Sci, 2019).
6. Karaa A, Haas R et al. MMPOWER-3 in primary mitochondrial myopathy: primary endpoint not met, secondary outcomes directional (Neurology, 2023).